Hashemi Reza, Peymani Maryam, Ghaedi Kamran, Saffar Hana
Department of Biology, Faculty of Basic Sciences, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran.
Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Science and Technology, University of Isfahan, Esfahän, Iran.
Med Oncol. 2022 Feb 12;39(5):57. doi: 10.1007/s12032-022-01661-8.
Investigating the specific pathways and their relation with survival, mutation, sensitivity, and resistance to various drugs in different stages of colorectal cancer (CRC) could be effective in cancer treatment. In this study, identifying the specific pathways in each stage of CRC compared to other stages was considered via meta-analytic methodology. The Cancer Genome Atlas (TCGA) data with gene set enrichment analysis (GSEA) software, and CRC RNA-Seq data were used to enrich and determine specific pathways as well as to evaluate the expression level of TOP RANK genes. In addition, The Cancer Cell Line Encyclopedia (CCLE) data were used to correlate candidate genes with drug resistance. Finally, using Gene Expression Omnibus (GEO) data, drugs that could affect the expression level of these genes were identified. Three specific molecular pathways, including oxidative phosphorylation (OXPHOS), regulation of transporter activity (RTA), and negative regulation of transmembrane receptor protein serine threonine kinase (NRSTK) have been identified as hub pathways for stages II, III, and IV, respectively (P < 0.01). The expression level of TOP RANK genes in each stage increased on average twice compared to other stages (P < 0.01), and CCNB1, DKK1, NOG genes were associated with survival in stages II and IV, respectively (P < 0.01). The expression of some selected genes had a correlation with drug resistance and sensitivity (P < 0.05). GEO data revealed that gamma-tocotrienol (g-T3), NSC319726, and Casiopeina Cas-II-gly may reduce the expression of, NDUFAF1, CCNB1, DKK1 genes, respectively (P < 0.01). Specific pathways and TOP RANK genes could lead to cancer progression and malignancy, resistance to chemotherapy drugs, poor survival in patients, and metastasis. Therefore, identification and targeting these pathways at each stage could be crucial in inhibiting progression at different stages of CRC.
研究结直肠癌(CRC)不同阶段的特定通路及其与生存、突变、敏感性和对各种药物耐药性的关系,可能对癌症治疗有效。在本研究中,通过荟萃分析方法,比较了CRC各阶段与其他阶段的特定通路。利用癌症基因组图谱(TCGA)数据和基因集富集分析(GSEA)软件,以及CRC RNA测序数据,来富集和确定特定通路,并评估排名靠前基因的表达水平。此外,利用癌细胞系百科全书(CCLE)数据,将候选基因与耐药性相关联。最后,利用基因表达综合数据库(GEO)数据,确定了可能影响这些基因表达水平的药物。已确定三条特定的分子通路,分别为氧化磷酸化(OXPHOS)、转运体活性调节(RTA)和跨膜受体蛋白丝氨酸苏氨酸激酶负调节(NRSTK),它们分别是II期、III期和IV期的核心通路(P < 0.01)。各阶段排名靠前基因的表达水平平均比其他阶段增加了两倍(P < 0.01),CCNB1、DKK1、NOG基因分别与II期和IV期的生存相关(P < 0.01)。一些选定基因的表达与耐药性和敏感性相关(P < 0.05)。GEO数据显示,γ-生育三烯酚(g-T3)、NSC319726和Casiopeina Cas-II-gly可能分别降低NDUFAF1、CCNB1、DKK1基因的表达(P < 0.01)。特定通路和排名靠前的基因可能导致癌症进展和恶性程度增加、对化疗药物耐药、患者生存不良以及转移。因此,在每个阶段识别并靶向这些通路,对于抑制CRC不同阶段的进展可能至关重要。